Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients

Oncology ◽  
2016 ◽  
Vol 91 (4) ◽  
pp. 194-204
Author(s):  
Rahul P. Bhandari ◽  
Jason D. Stanford ◽  
Satya Packianathan ◽  
William N. Duggar ◽  
Madhava R. Kanakamedala ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Stereotactic Body Radiation Therapy ◽  
Small Cell ◽  
Single Center ◽  
Small Cell Lung ◽  
Single Center Study ◽  
Center Study

An observational single-center study of nivolumab in Indian patients with recurrent advanced non-small cell lung cancer

2019 ◽  
Vol 56 (4) ◽  
pp. 315 ◽  
Author(s):  
Naresh Somani ◽  
Pawan Agarwal ◽  
Harish Singhal ◽  
AbhishekK Singh ◽  
Abhilasha Sinha ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Single Center ◽  
Small Cell Lung ◽  
Indian Patients ◽  
Single Center Study ◽  
Center Study

scholarly journals Chemotherapy with Cisplatin and Pemetrexed for Non-Small Cell Lung Cancer Patients: a Retrospective Single Center Study

2014 ◽  
Vol 25 ◽  
pp. v82
Author(s):  
Yoshimasa Shiraishi ◽  
Ryo Toyozawa ◽  
Eiko Inamasu ◽  
Gouji Toyokawa ◽  
Tomoyoshi Takenaka ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Single Center ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Single Center Study ◽  
Center Study

Survival of M1a Non-Small Cell Lung Cancer Treated Surgically: A Retrospective Single-Center Study

2015 ◽  
Vol 63 (07) ◽  
pp. 577-582 ◽  
Author(s):  
Tieqin Liu ◽  
Gebang Wang ◽  
Chenlei Zhang ◽  
Bingbing Liu ◽  
Hongxu Liu
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Single Center ◽  
Small Cell Lung ◽  
Single Center Study ◽  
Center Study

scholarly journals P3-238: Long term prognosis after resection for non-small cell lung cancer: Single center study

2007 ◽  
Vol 2 (8) ◽  
pp. S781
Author(s):  
Hyun Joo Lee ◽  
Seung Il Park ◽  
Dong Kwan Kim ◽  
Yong Hee Kim ◽  
Yong Jik Lee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Single Center ◽  
Small Cell Lung ◽  
Single Center Study ◽  
Long Term Prognosis ◽  
Center Study

scholarly journals Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study

2020 ◽  
Vol 8 (2) ◽  
pp. e001302
Author(s):  
Suchita Pakkala ◽  
Kristin Higgins ◽  
Zhengjia Chen ◽  
Gabriel Sica ◽  
Conor Steuer ◽  
...  
Keyword(s):  
Lung Cancer ◽  
T Cells ◽  
Radiation Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Peripheral Blood ◽  
Stereotactic Body Radiation Therapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stereotactic Body Radiation

BackgroundImmune checkpoint blockade (ICB) targeting programmed cell death protein 1 and cytotoxic T lymphocyte-associated protein 4 has achieved modest clinical activity as salvage therapy in relapsed small cell lung cancer (SCLC). We conducted this signal-finding study to assess the efficacy of ICB with or without radiation in relapsed SCLC.MethodsPatients with relapsed SCLC and ≤2 previous lines of therapy were randomized to (1) arm A: durvalumab (D) 1500 mg/tremelimumab (T) 75 mg (intravenously every 4 weeks without stereotactic body radiation therapy (SBRT)) or (2) arm B: immune-sensitizing SBRT to one selected tumor site (9 Gy × 3 fractions) followed by D/T. Treatment continued until progression or a maximum of 12 months. The co-primary endpoints of the study were overall response rate (ORR) and progression-free survival (PFS). We evaluated circulating lymphocyte repertoire in serial peripheral blood samples and tumor infiltrating lymphocytes (TILs) from on-treatment biopsies as pharmacodynamic markers.ResultsEighteen patients were randomized to arms A and B (n=9 each): median age 70 years; 41.2% women. The median PFS and ORR were 2.1 months and 0% in arm A and 3.3 months and 28.6% in arm B. The median overall survival (OS) was 2.8 months in arm A and 5.7 months in arm B (p=0.3772). Pooled efficacy of D/T±SBRT in 15 Response evaluation criteria in solid tumors (RECIST) evaluable patients across both arms showed the best ORR in terms of partial response in 13.3%, stable disease in 26.6% and progressive disease in 60.0%; the overall median PFS and OS were 2.76 and 3.9 months. The most common adverse events were grade 1 fatigue (66%) and grade 1 elevated amylase (56%) in arm A, and grade 1 fatigue (56%) and pain (44%) in arm B. There was a significant increase in activated CD8(+)ICOS+ T cells (p=0.048) and a reduction in naïve T cells (p=0.0454) in peripheral blood following treatment, along with a significant amount of activated CD8+ICOS+ T cells in TILs from responders.ConclusionsThe D/T combination with and without SBRT was safe but did not show sufficient efficacy signal in relapsed SCLC. Changes in peripheral blood lymphocyte and TILs were consistent with an immunologic response.Trial registration numberNCT02701400.

scholarly journals A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer

2017 ◽  
Vol 154 (2) ◽  
pp. 675-686.e4 ◽  
Author(s):  
Babatunde A. Yerokun ◽  
Chi-Fu Jeffrey Yang ◽  
Brian C. Gulack ◽  
Xuechan Li ◽  
Michael S. Mulvihill ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Stereotactic Body Radiation Therapy ◽  
Wedge Resection ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stage Ia ◽  
National Analysis
Sign in / Sign up

Export Citation Format

Share Document